Gain comprehensive visibility and streamlined access to the US domestic cord blood unit inventory.
Cord Blood Units for Allogeneic Cell Therapy Source Material
Gain comprehensive visibility and streamlined access to the US domestic cord blood unit inventory.
Access cryopreserved cord blood units with diverse specifications
| Clinical and commercial use | Non-clinical use | |
| Licensed cord blood unit | Unlicensed cord blood unit | Research use only |
| Manufactured as a GMP-grade cellular product | Manufactured as a GMP-grade cellular product | Manufactured as a GMP-grade cellular product |
| Meets donor eligibility and safety requirements for use in humans | Meets donor eligibility and safety requirements for use in humans | Similarly manufactured and characterized, but does not meet eligibility and safety requirements for use in humans |
| Meets FDA licensure requirements for allogeneic transplant | Missing one or more specifications required in the BLA to support allogeneic transplant | Intended for: · Validating, qualifying and investigating internal procedures and processes · Engineering runs |
| Must be released for licensed indication (currently HPC reconstitution) or under IND if off-label | Must be released under IND if intended for use in humans | |
Our NMDP Registry℠ database contains extensive information about each CBU to allow for therapy-matched unit identification. Our experienced team uses our established logistics and supply chain management process to coordinate the safe transport and delivery of the valuable cryopreserved CBUs.
Specifications available for cord blood units include:
Total nucleated cell (TNC) and CD34+ counts
Viability and volume
HLA and blood type
Donor eligibility safety profile
Unit age
Licensure status
Simplifying sourcing through the NMDP BioTherapies Cord Blood Bank Alliance
Our NMDP BioTherapies Cord Blood Bank Alliance offers a single point of access to the CBUs needed for allogeneic cell therapy development. We qualify and contract with high-performing cord blood banks that are motivated to supply their CBUs for emerging cell therapy development and commercialization.
NMDP BioTherapies understands the varying capabilities of each bank, so developers receive cord blood material from the banks that best match their needs. Member banks’ cryopreserved CBUs are listed on the NMDP Registry of more than 270,000 fully characterized domestic cord blood units.
Member cord blood bank participation requirements include:
Accredited by AABB or NetCord-FACT
Abide by NMDP Standards
Completion of NMDP quality system audit
Meet Quality System essentials such as Facility, Personnel, Administration and Support Services requirements
Comply with World Marrow Donor Association Standards
Current NMDP BioTherapies Cord Blood Bank Alliance members
Contracted Alliance members have a demonstrated and long-standing commitment to serving patient needs. Each bank is a member of the NMDP℠ Network and has a history of providing high-quality cord blood grafts for hematopoietic stem cell transplant.
Explore matched offerings
Find solutions for allogeneic cord blood units that match a patient’s human leukocyte antigens.